ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of GBP 27.71 billion. The enterprise value is 27.64 billion.

Market Cap	27.71B
Enterprise Value	27.64B

Important Dates

The next estimated earnings date is Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	May 8, 2025

Share Statistics

Current Share Class	146.37M
Shares Outstanding	n/a
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	-0.18%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.44M

Valuation Ratios

The trailing PE ratio is 27.27 and the forward PE ratio is 25.23.

PE Ratio	27.27
Forward PE	25.23
PS Ratio	7.13
PB Ratio	6.46
P/TBV Ratio	15.79
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.75, with an EV/FCF ratio of 22.76.

EV / Earnings	27.19
EV / Sales	7.50
EV / EBITDA	20.75
EV / EBIT	23.30
EV / FCF	22.76

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.15.

Current Ratio	3.41
Quick Ratio	2.06
Debt / Equity	0.15
Debt / EBITDA	0.46
Debt / FCF	0.54
Interest Coverage	139.28

Financial Efficiency

Return on equity (ROE) is 25.81% and return on invested capital (ROIC) is 16.54%.

Return on Equity (ROE)	25.81%
Return on Assets (ROA)	14.01%
Return on Invested Capital (ROIC)	16.54%
Return on Capital Employed (ROCE)	24.33%
Revenue Per Employee	389,440
Profits Per Employee	101,848
Employee Count	9,980
Asset Turnover	0.70
Inventory Turnover	2.09

Taxes

In the past 12 months, ResMed has paid 204.33 million in taxes.

Income Tax	204.33M
Effective Tax Rate	16.74%

Stock Price Statistics

The stock price has increased by +38.03% in the last 52 weeks. The beta is 0.77, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	+38.03%
50-Day Moving Average	241.97
200-Day Moving Average	238.28
Relative Strength Index (RSI)	71.83
Average Volume (20 Days)	154

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.80

Income Statement

In the last 12 months, ResMed had revenue of GBP 3.89 billion and earned 1.02 billion in profits. Earnings per share was 6.90.

Revenue	3.89B
Gross Profit	2.31B
Operating Income	1.25B
Pretax Income	1.22B
Net Income	1.02B
EBITDA	1.37B
EBIT	1.25B
Earnings Per Share (EPS)	6.90

Full Income Statement

Balance Sheet

The company has 731.30 million in cash and 649.98 million in debt, giving a net cash position of 81.32 million.

Cash & Cash Equivalents	731.30M
Total Debt	649.98M
Net Cash	81.32M
Net Cash Per Share	n/a
Equity (Book Value)	4.29B
Book Value Per Share	29.28
Working Capital	1.76B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.28 billion and capital expenditures -65.14 million, giving a free cash flow of 1.21 billion.

Operating Cash Flow	1.28B
Capital Expenditures	-65.14M
Free Cash Flow	1.21B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.37%, with operating and profit margins of 32.10% and 26.15%.

Gross Margin	59.37%
Operating Margin	32.10%
Pretax Margin	31.41%
Profit Margin	26.15%
EBITDA Margin	35.14%
EBIT Margin	32.10%
FCF Margin	31.24%

Dividends & Yields

This stock pays an annual dividend of 1.64, which amounts to a dividend yield of 0.65%.

Dividend Per Share	1.64
Dividend Yield	0.65%
Dividend Growth (YoY)	7.19%
Years of Dividend Growth	3
Payout Ratio	23.14%
Buyback Yield	0.07%
Shareholder Yield	0.72%
Earnings Yield	3.67%
FCF Yield	4.38%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.61 and a Piotroski F-Score of 8.

Altman Z-Score	12.61
Piotroski F-Score	8